In-Body CAR-T Cell Engineering: A New Approach to Cancer Treatment
CAR-T cell therapy has emerged as a powerful tool against certain cancers, but the current approach requires extracting a patient's T cells, engineering them in a laboratory, and then reinfusing them—a process that is time-consuming and expensive. Scientists at UC San Francisco have now demonstrated a method to perform this genetic engineering directly inside the body.
The team developed a two-particle delivery system capable of targeting T cells specifically. This system can deliver both CRISPR gene-editing tools and new cancer-targeting DNA directly into T cells circulating in the bloodstream. The DNA is inserted at a precise location in the genome, allowing the cells to be reprogrammed into CAR-T cells without ever leaving the patient's body.
By eliminating the laboratory manipulation steps, this approach could significantly reduce the time and cost associated with CAR-T therapy. It also has the potential to make the treatment more accessible by simplifying the manufacturing process. The precision of the genome insertion helps ensure that the modifications are stable and targeted.
The research represents an early but promising step toward simplifying immunotherapy production. Further studies will be needed to confirm the safety and efficacy of this in-body engineering approach in clinical settings.